SynthesisAsian Pacific journal of cancer prevention : APJCP2025
Chronic Infections as Catalysts for Melanoma Aggressiveness: Insights into Tumour Microenvironment Modulation.
Synthesis in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Peptidergic Systems for Melanoma Treatment.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous melanoma is a highly aggressive skin cancer known for its metastatic potential and resistance to conventional therapies. While genetic and environmental factors are well-recognized in melanoma progression, the impact of chronic microbial infections is not fully understood. Recent studies suggest microbial pathogens interact with the tumour microenvironment, facilitating immune evasion, epithelial-mesenchymal transition (EMT), and therapy resistance. This study aims to explore how chronic infections contribute to melanoma aggressiveness and assess the potential of antimicrobial peptides (AMPs) as a new therapeutic approach.
methodsA systematic review was conducted according to PRISMA 2020 guidelines, utilising academic databases (PubMed, Scopus, Web of Science, and Google Scholar) from 2020 to 2025. Peer-reviewed studies were screened to identify microbial species linked to melanoma, antimicrobial resistance (AMR), and the effectiveness of AMPs. Data on cytokines, immune pathways, and bioinformatics approaches to AMP design were synthesized.
resultsThe review revealed that pathogens such as Staphylococcus aureus, Pseudomonas aeruginosa, and Candida tropicalis exacerbate melanoma progression by inducing chronic inflammation, promoting pro-inflammatory cytokines (IL-6, TNF-α), and enhancing EMT, which aids tumour invasion and metastasis. AMR complicates treatment, particularly in immunocompromised patients. AMPs were identified as promising agents due to their dual action: antimicrobial activity and immunomodulation. Advances in bioinformatics and AI have facilitated the rational design of AMPs with improved specificity and reduced cytotoxicity, suggesting potential synergy with immune checkpoint inhibitors and targeted therapies.
conclusionChronic microbial infections significantly influence melanoma aggressiveness and treatment resistance. AMPs offer a promising, multifunctional therapeutic approach, addressing infection control and tumour microenvironment modulation. Combining AMPs with current immunotherapies may enhance melanoma management. Further research and clinical trials are needed to validate and optimise AMP-based treatments for personalised care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.